Statistics for TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Total visits
| views | |
|---|---|
| TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer | 74 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| Rimawi2019TBCRC023-AAM.pdf | 205 |
| java.util.UUID:7c75a54e-94b8-4541-ad56-e9b20810fa0d | 70 |
| java.util.UUID:928c8647-92c5-4be9-8e46-b7a5046e5117 | 14 |
| java.util.UUID:accc1fc7-9871-417a-a195-00630136a8ac | 8 |
Top country views
| views | |
|---|---|
| United States | 63 |
| China | 1 |
| Japan | 1 |
| South Korea | 1 |
| Malaysia | 1 |
| Norway | 1 |
| Russia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 43 |
| Fairfield | 6 |
| Houston | 5 |
| Cambridge | 3 |
| Ann Arbor | 1 |
| Baltimore | 1 |
| Beijing | 1 |
| Irkutsk | 1 |
| Seremban | 1 |
| Stavanger | 1 |